SurModics Inc

SurModics — Investor Presentation (June 2023)

43 slides from SurModics's investor presentation, Jun 8, 2023

  1. Slide 1: Surmodics June 2023 Investor Presentation

    Gary Maharaj President and CEO Tim Arens Senior Vice President of Finance, IT and CFO June 2023 © 2023 Surmodics, Inc. All rights reserved. EXHIBIT 99.1

  2. Slide 2: Safe Harbor

    Safe Harbor © 2023 Surmodics, Inc. All rights reserved. Caution: SURVEIL, SUNDANCE and AVESS Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. Some of the statements made during this presentation may be considered forward-looking stat

  3. Slide 3: Surmodics at a Glance

    © 2023 Surmodics, Inc. All rights reserved. Surmodics at a Glance We are a Medical Technology company focused on driving innovation to improve the prevention and detection of disease. (NASDAQ: SRDX) (1)As of March 31, 2023 Year Founded: 1979 Locations: Minneapolis, MN Ballinasloe, Ireland Total Empl

  4. Slide 4: Investment Highlights

    Investment Highlights Core businesses operate at a significant commercial scale, generating strong, predictable cash flow Multiple, innovative vascular intervention devices to accelerate revenue growth profile Vascular intervention devices focused on large, underpenetrated markets: $3.8B addressable

  5. Slide 5: Experienced Leadership Team

    Experienced Leadership Team © 2023 Surmodics, Inc. All rights reserved. Gary R. Maharaj President and Chief Executive Officer (Joined 2010) Timothy J. Arens Senior Vice President of Finance and Information Technology and Chief Financial Officer (Joined 2007) Joseph J. Stich Senior Vice President of

  6. Slide 6: Where we are today and where we’re headed…

    Where we are today and where we’re headed… © 2023 Surmodics, Inc. All rights reserved. Core Businesses: Medical Device Performance Coatings & In Vitro Diagnostics (IVD) Components Growth Opportunity: Vascular Intervention Devices Differentiated drug-coated balloon, thrombectomy and radial access dev

  7. Slide 7: Vascular Interventions: Product Portfolio and Pipeline

    Vascular Interventions: Product Portfolio and Pipeline RADIAL ACCESS PORTFOLIO For Peripheral Interventions DRUG-COATED BALLOONS For Lower-limb Interventions MECHANICAL THROMBECTOMY For Arterial and Venous Clot Removal PRE-COMMERCIAL PRE-COMMERCIAL (FOR ARTERIAL THROMBECTOMY) PRE-COMMERCIAL Caution:

  8. Slide 8: Vascular Interventions: Addressing large, underpenetrated markets in the U.S.

    Vascular Interventions: Addressing large, underpenetrated markets in the U.S. © 2023 Surmodics, Inc. All rights reserved. Addressable Market Opportunity Condition(s) Addressed Market Penetration(1) Market Growth (3-Year CAGR) Product Platform Peripheral Artery Disease Above-the-Knee Peripheral Arter

  9. Slide 9: Fiscal 2023 Strategic Objectives

    Fiscal 2023 Strategic Objectives © 2023 Surmodics, Inc. All rights reserved. SurVeil™ Drug-Coated Balloon Advance regulatory strategy with the goal of achieving FDA Pre-Market Approval (PMA) 1 Pounce™ Thrombectomy (Arterial) and Sublime™ Radial Access platforms Develop direct sales force and advance

  10. Slide 10: Caution: SURVEIL Drug-Coated Balloons are investigational devices

    © 2023 Surmodics, Inc. All rights reserved. Caution: SURVEIL Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use.

  11. Slide 11: SurVeil DCB: Product Overview

    SurVeil™ DCB: Product Overview © 2023 Surmodics, Inc. All rights reserved. Overview Designed to treat peripheral artery disease in the vessels above the knee using a proprietary drug-excipient formulation to reduce the likelihood of restenosis Advantages Designed to deliver similar therapeutic outco

  12. Slide 12: SurVeil DCB: Market Opportunity & Commercial Strategy

    SurVeil™ DCB: Market Opportunity & Commercial Strategy © 2023 Surmodics, Inc. All rights reserved. ~120,000 $1B ~25% Penetration(2) Peripheral Artery Disease Above-the-knee Annual, Addressable U.S. Market(1) Annual, Addressable Above-the-knee Procedures Annual Above-the-Knee DCB Procedures ~500,000

  13. Slide 13: Caution: Federal (US) law restricts this device

    © 2023 Surmodics, Inc. All rights reserved. Caution: Federal (US) law restricts this device to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.

  14. Slide 14: Pounce Thrombectomy System (Arterial): Product Overview

    Pounce™ Thrombectomy System (Arterial): Product Overview © 2023 Surmodics, Inc. All rights reserved. Overview Designed to capture and remove clots from occluded arteries in the peripheral vasculature Advantages Designed to provide efficient and effective clot removal, restoring blood flow quickly wi

  15. Slide 15: Pounce Thrombectomy System (Arterial): Market Opportunity & Commercial Strategy

    Pounce™ Thrombectomy System (Arterial): Market Opportunity & Commercial Strategy © 2023 Surmodics, Inc. All rights reserved. Commercializing Pounce™ Thrombectomy System in the U.S. via direct sales force: FY’22 achievements: Hired and onboarded direct sales force Scaled commercialization to include

  16. Slide 16: Caution: Federal (US) law restricts this device

    © 2023 Surmodics, Inc. All rights reserved. Caution: Federal (US) law restricts this device to sale by or on the order of a physician. Please refer to Instructions for Use for indications, contraindications, warnings, and precautions.

  17. Slide 17: Sublime Radial Access: Platform Overview

    Sublime™ Radial Access: Platform Overview Radial Access is the new frontier in peripheral interventions, with significant benefits, compared with standard transfemoral access, for patients and practitioners alike Reduced complications 50–80% relative risk reduction in access site complication1,2 Red

  18. Slide 18: The Sublime Radial Access Platform

    The Sublime™ Radial Access Platform © 2023 Surmodics, Inc. CONFIDENTIAL All rights reserved. SRDX-SRA-619 B SURMODICS, SUBLIME and the SURMODICS and SUBLIME logos are trademarks of Surmodics Inc. and/or its affiliates. Caution: Federal (US) law restricts this device to sale by or on the order of a p

  19. Slide 19: Sublime Radial Access: Market Opportunity & Commercial Strategy

    Sublime™ Radial Access: Market Opportunity & Commercial Strategy © 2023 Surmodics, Inc. All rights reserved. Radial Access Annual Addressable U.S. Market(1) Patients treated with radial access interventions ~75,000 Patients treated with ATK or BTK Interventions 840,000 Patient figures and market pen

  20. Slide 20: Financial Summary

    © 2023 Surmodics, Inc. All rights reserved. Financial Summary

  21. Slide 21: Significant Commercial Scale with Multiple Catalysts for Future Growth

    © 2023 Surmodics, Inc. All rights reserved. Significant Commercial Scale with Multiple Catalysts for Future Growth (1) Midpoint of guidance ranging from $103 - $106 million $81.3 $100.1 $94.9 $105.1 $100.0 $104.5(1) 5-year CAGR of 6.5% through FY’22 FY’23 Revenue growth to benefit from: Contribution

  22. Slide 22: FY’23 Financial Guidance Overview

    © 2023 Surmodics, Inc. All rights reserved. FY’23 Financial Guidance Overview Total Revenue: $103 to $106 million, up 3% to 6% year-over-year GAAP Diluted Loss per Share(1): $(2.30) to $(2.00), compared to $(1.96) in FY’22 Non-GAAP Diluted Loss per Share(2): $(1.98) to $(1.68), compared to $(0.95) i

  23. Slide 23: Available Capital & Capital Allocation Priorities

    © 2023 Surmodics, Inc. All rights reserved. Available Capital & Capital Allocation Priorities Focused on maintaining liquidity, ensuring access to capital and enhancing cash management… …while positioning Surmodics to generate strong, sustainable growth and enhance future value Available Capital ($M

  24. Slide 24: Key Developments & Related Expectations

    © 2023 Surmodics, Inc. All rights reserved. Key Developments & Related Expectations

  25. Slide 25: Substantial Progress Toward Attainment of the SurVeil PMA Approval

    © 2023 Surmodics, Inc. All rights reserved. Substantial Progress Toward Attainment of the SurVeil PMA Approval Caution: SURVEIL Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. Recently, we filed our amended PMA application with the

  26. Slide 26: Market Development of Pounce and Sublime is Gaining Traction

    © 2023 Surmodics, Inc. All rights reserved. Our Market Development of Pounce™ Thrombectomy and Sublime™ Radial Access is Gaining Traction Pounce™ Thrombectomy (Arterial) and Sublime™ Radial Access platforms together are becoming a growth catalyst The customer base has been and is expected to continu

  27. Slide 27: We are Focused on Improving Cash Flow

    We are Focused on Improving Cash Flow © 2023 Surmodics, Inc. All rights reserved. Cash flow improvement to come from multiple sources We recently implemented a spending reduction plan and communicated expectations to reduce our quarterly cash use to approximately $3.5-$4.0 million beginning Q3 FY’23

  28. Slide 28: Summary: Significant Upside Potential

    Summary: Significant Upside Potential Surmodics’ experienced leadership team is executing a multi-year strategy to drive sustainable, long-term profitable growth Our core businesses continue to operate at a significant commercial scale, generating strong, predictable cash flow The successful commerc

  29. Slide 29: Trademarks

    © 2023 Surmodics, Inc. All rights reserved. SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE, AVESS, TELEMARK, SERENE and the SURMODICS, SUBLIME, POUNCE, SURVEIL, SUNDANCE and AVESS logos are trademarks of Surmodics Inc. and/or its affiliates. All third-party trademarks are trademarks of their respecti

  30. Slide 30: Appendix

    © 2023 Surmodics, Inc. All rights reserved. Appendix

  31. Slide 31: Strategic Agreement with Abbott

    © 2023 Surmodics, Inc. All rights reserved. Strategic Agreement with Abbott February 27, 2018 – Abbott and Surmodics Announced Agreement for Next-Generation Drug-Coated Balloon Development and Commercialization Exclusive worldwide commercialization rights for SurVeil™ drug-coated balloon (DCB) for s

  32. Slide 32: SurVeil DCB: Impact to Financials

    © 2023 Surmodics, Inc. All rights reserved. Surveil™ DCB: Impact to Financials Caution: SURVEIL Drug-Coated Balloons are investigational devices. Limited by Federal (or United States) law to investigational use. TRANSCEND costs incurred following the execution of the SurVeil™ DCB development and dis

  33. Slide 33: © 2023 Surmodics, Inc. All rights reserved.

    © 2023 Surmodics, Inc. All rights reserved.

  34. Slide 34: Pounce Venous Thrombectomy: Product Overview

    Pounce Venous Thrombectomy: Product Overview © 2023 Surmodics, Inc. All rights reserved. Overview Designed to separate, macerate and remove clots from occluded veins in the peripheral vasculature Advantages Shorter device profile, compared to competitive mechanical devices, simplifies the procedure

  35. Slide 35: Pounce Venous Thrombectomy: Market Opportunity & Commercial Strategy

    Pounce™ Venous Thrombectomy: Market Opportunity & Commercial Strategy © 2023 Surmodics, Inc. All rights reserved. Venous clot removal, Including Deep Vein Thrombosis (DVT)(1) Annual, Addressable U.S. Market Patients treated with mechanical thrombectomy 44,000 Addressable Procedures(1) 270,000 Our de

  36. Slide 36: Sundance Sirolimus-coated Balloon: Product Overview

    © 2023 Surmodics, Inc. All rights reserved. Sundance™ Sirolimus-coated Balloon: Product Overview Hydrophilic shaft coating Surmodics Serene™ hydrophilic coating Surmodics .014” PTA platform 2 – 4 mm diameter 20 – 220 mm lengths Uniform sirolimus drug coating Sirolimus + Proprietary Excipient 360° un

  37. Slide 37: Medical Device Performance Coatings

    © 2023 Surmodics, Inc. All rights reserved. Medical Device Performance Coatings

  38. Slide 38: The Magic Is In The Coating

    The Magic Is In The Coating Cardiovascular Royalty Rev = 25-35% CAGR = (1)-2% Neurological Royalty Rev = 25-35% CAGR = 5-9% Peripheral Vascular Royalty Rev = 25-35% CAGR = 4-6% Structural Heart Royalty Rev = <10% CAGR = 12–15% 25%-35% <10% ROYALTY REVENUE DISTRIBUTION1,2 Estimated Distribution of Su

  39. Slide 39: A Stable Foundation For Future Growth

    (1) Over 150 license agreements among 100 customers 34 U.S. patents issued; 79 International patents Issued Royalty rates for new licenses typically range from 2-3% for the device application Product gross margins on the high end of medical device industry averages Our Medical Device Performance Coa

  40. Slide 40: In Vitro Diagnostics (IVD)

    © 2023 Surmodics, Inc. All rights reserved. In Vitro Diagnostics (IVD)

  41. Slide 41: Leading Provider of Components for In Vitro Diagnostic (IVD) Tests

    Leading Provider of Components for In Vitro Diagnostic (IVD) Tests In Vitro Diagnostics Our components are used in test kits sold by the majority of the top ten global in vitro diagnostics companies > 1000 unique customers in several categories: Kit manufacturers, R&D institutions, Distributors and

  42. Slide 42: Continued Outstanding Results

    © 2023 Surmodics, Inc. All rights reserved. Continued Outstanding Results IN VITRO DIAGNOSTICS Growth: 8% 14% 3% Our IVD business is expected to continue to deliver low-to-mid-single digit revenue growth annually Strong and growing customer base with broad portfolio of differentiated products Strong

  43. Slide 43: Clinical Advisors

    Clinical Advisors Renu Virmani, MD, FACC Clinical Advisor — Cardiovascular Pathologist CVPath Ken Rosenfield, MD Chair Advisory Board — Interventional Cardiology Massachusetts General Hospital Gary Ansel, MD, FACC Clinical Advisor — Interventional Cardiology Healthcare Insights Marianne Brodmann MD,

Surmodics — Investor Presentation (June 2023) on 6ix